Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Provided informed consent~* Adult men or women \>= 18 years~* Chronic plaque psoriasis for at least 6 months~* Baseline psoriasis activity and severity index \>= 12 and body surface area \>= 10 % and Physician's Global Assessments score \>= 3~* Candidate for systemic psoriasis therapy and/or phototherapy and/or chemophototherapy~* Other protocol-defined inclusion criteria may apply~Exclusion Criteria:~* Erythrodermic, guttate, generalized pustular form of psoriasis~* History of current, chronic, or recurrent infections of viral, bacterial, or fungal origin as described in the protocol~* Congestive heart failure~* History of a lymphoproliferative disorder including lymphoma or current signs and symptoms suggestive of lymphoproliferative disease~* Concurrent malignancy or a history of malignancy as described in the protocol~* History of, or suspected, demyelinating disease of the central nervous system (e.g., multiple sclerosis or optic neuritis)~* Female subjects who are breastfeeding, pregnant, or plan to become pregnant during the study or within 5 months following last dose of study drug (in Czech Republic and Germany) and within 3 months for all other countries. Male subjects who are planning a partner pregnancy during the study or within 10 weeks following the last dose of study drug~* Any other condition which, in the Investigator's judgment, would make the subject unsuitable for participation in the study~* Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CZP 200 mg (Type: EXPERIMENTAL): CZP 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.~Treatment received from Week 16-48 is based on initial treatment and response to treatment:~* PASI50 responders at Week 16 continue to receive CZP 200 mg Q2W.~* PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to unblinded CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~* PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W.~Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Depending on PASI50 or PASI75 responses at Week 60 or a later time point, subjects may switch to CZP 400 mg Q2W or withdraw from the study.
- CZP 400 mg (Type: EXPERIMENTAL): CZP 400 mg every two weeks (Q2W) through Week 14.~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~* PASI50 responders at Week 16 continue to receive CZP 400 mg Q2W.~* PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~* PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension (OLE) Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Subjects who achieve a PASI75 response during the OLE Phase may switch to CZP 200 mg Q2W.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo subcutaneous (sc) injection every two weeks (Q2W).~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~* PASI50 responders at Week 16, who do not achieve a PASI75 response at Week 16 receive CZP 400 mg at Weeks 16, 18 and 20 (loading doses) followed by CZP 200 mg Q2W starting at Week 22.~* PASI75 responders at Week 16 continue to receive Placebo.~* PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~* PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.

Based on this trial design, predict the completion outcome and termination type (if applicable).